These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

293 related items for PubMed ID: 17020973

  • 1. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas.
    Hormigo A, Gu B, Karimi S, Riedel E, Panageas KS, Edgar MA, Tanwar MK, Rao JS, Fleisher M, DeAngelis LM, Holland EC.
    Clin Cancer Res; 2006 Oct 01; 12(19):5698-704. PubMed ID: 17020973
    [Abstract] [Full Text] [Related]

  • 2. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma.
    Tanwar MK, Gilbert MR, Holland EC.
    Cancer Res; 2002 Aug 01; 62(15):4364-8. PubMed ID: 12154041
    [Abstract] [Full Text] [Related]

  • 3. YKL-40 and MMP-9 as serum markers for patients with primary central nervous system lymphoma.
    Hottinger AF, Iwamoto FM, Karimi S, Riedel E, Dantis J, Park J, Panageas KS, Lassman AB, Abrey LE, Fleisher M, Holland EC, DeAngelis LM, Hormigo A.
    Ann Neurol; 2011 Jul 01; 70(1):163-9. PubMed ID: 21391238
    [Abstract] [Full Text] [Related]

  • 4. Serum YKL-40 is a marker of prognosis and disease status in high-grade gliomas.
    Iwamoto FM, Hottinger AF, Karimi S, Riedel E, Dantis J, Jahdi M, Panageas KS, Lassman AB, Abrey LE, Fleisher M, DeAngelis LM, Holland EC, Hormigo A.
    Neuro Oncol; 2011 Nov 01; 13(11):1244-51. PubMed ID: 21831900
    [Abstract] [Full Text] [Related]

  • 5. Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer.
    Yamac D, Ozturk B, Coskun U, Tekin E, Sancak B, Yildiz R, Atalay C.
    Adv Ther; 2008 Aug 01; 25(8):801-9. PubMed ID: 18670741
    [Abstract] [Full Text] [Related]

  • 6. High serum YKL-40 level after surgery for colorectal carcinoma is related to short survival.
    Cintin C, Johansen JS, Christensen IJ, Price PA, Sørensen S, Nielsen HJ.
    Cancer; 2002 Jul 15; 95(2):267-74. PubMed ID: 12124825
    [Abstract] [Full Text] [Related]

  • 7. Locally advanced breast carcinoma treated with neoadjuvant chemotherapy: are the changes in serum levels of YKL-40, MMP-2 and MMP-9 correlated with tumor response?
    Coskun U, Yamac D, Gulbahar O, Sancak B, Karaman N, Ozkan S.
    Neoplasma; 2007 Jul 15; 54(4):348-52. PubMed ID: 17845129
    [Abstract] [Full Text] [Related]

  • 8. High serum levels of YKL-40 in patients with squamous cell carcinoma of the head and neck are associated with short survival.
    Roslind A, Johansen JS, Christensen IJ, Kiss K, Balslev E, Nielsen DL, Bentzen J, Price PA, Andersen E.
    Int J Cancer; 2008 Feb 15; 122(4):857-63. PubMed ID: 17957792
    [Abstract] [Full Text] [Related]

  • 9. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer.
    Jensen BV, Johansen JS, Price PA.
    Clin Cancer Res; 2003 Oct 01; 9(12):4423-34. PubMed ID: 14555515
    [Abstract] [Full Text] [Related]

  • 10. High serum YKL-40 levels in patients with primary breast cancer is related to short recurrence free survival.
    Johansen JS, Christensen IJ, Riisbro R, Greenall M, Han C, Price PA, Smith K, Brünner N, Harris AL.
    Breast Cancer Res Treat; 2003 Jul 01; 80(1):15-21. PubMed ID: 12889595
    [Abstract] [Full Text] [Related]

  • 11. YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas.
    Nutt CL, Betensky RA, Brower MA, Batchelor TT, Louis DN, Stemmer-Rachamimov AO.
    Clin Cancer Res; 2005 Mar 15; 11(6):2258-64. PubMed ID: 15788675
    [Abstract] [Full Text] [Related]

  • 12. Plasma YKL-40: a potential new cancer biomarker?
    Johansen JS, Schultz NA, Jensen BV.
    Future Oncol; 2009 Sep 15; 5(7):1065-82. PubMed ID: 19792974
    [Abstract] [Full Text] [Related]

  • 13. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma.
    Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, von der Maase H.
    Cancer; 2006 Mar 01; 106(5):1130-9. PubMed ID: 16456816
    [Abstract] [Full Text] [Related]

  • 14. Serum markers in early-stage and locally advanced melanoma.
    Lugowska I, Kowalska M, Fuksiewicz M, Kotowicz B, Mierzejewska E, Koseła-Paterczyk H, Szamotulska K, Rutkowski P.
    Tumour Biol; 2015 Nov 01; 36(11):8277-85. PubMed ID: 26002577
    [Abstract] [Full Text] [Related]

  • 15. YKL-40 is directly produced by tumor cells and is inversely linked to EGFR in glioblastomas.
    Horbinski C, Wang G, Wiley CA.
    Int J Clin Exp Pathol; 2010 Jan 01; 3(3):226-37. PubMed ID: 20224722
    [Abstract] [Full Text] [Related]

  • 16. Serum YKL-40, a new prognostic biomarker in cancer patients?
    Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA.
    Cancer Epidemiol Biomarkers Prev; 2006 Feb 01; 15(2):194-202. PubMed ID: 16492905
    [Abstract] [Full Text] [Related]

  • 17. YKL-40 and matrix metalloproteinases as potential biomarkers of inflammation and fibrosis in the development of bronchiolitis obliterans syndrome.
    Kastelijn EA, van Moorsel CH, Ruven HJ, Korthagen NM, Kwakkel-van Erp JM, van de Graaf EA, Zanen P, van Kessel DA, Grutters JC.
    Sarcoidosis Vasc Diffuse Lung Dis; 2013 Mar 01; 30(1):28-35. PubMed ID: 24003532
    [Abstract] [Full Text] [Related]

  • 18. Diagnostic and prognostic value of preoperative combined GFAP, IGFBP-2, and YKL-40 plasma levels in patients with glioblastoma.
    Gállego Pérez-Larraya J, Paris S, Idbaih A, Dehais C, Laigle-Donadey F, Navarro S, Capelle L, Mokhtari K, Marie Y, Sanson M, Hoang-Xuan K, Delattre JY, Mallet A.
    Cancer; 2014 Dec 15; 120(24):3972-80. PubMed ID: 25139333
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.